KRAS-Mutant Pancreatic CancerPhase 1NCT07671339
ELI-002 7P + mFOLFIRINOX ± Tislelizumab
ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
5 Phase 1 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Pancreas5 studies
KRAS-Mutant Pancreatic CancerPhase 1NCT07671339
ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Metastatic Pancreatic AdenocarcinomaPhase 1/2NCT03608631Papers
IExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
Metastatic MTAP-Deleted Solid TumorsPhase 1/2NCT07594626
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Metastatic Pancreatic Ductal Adenocarcinoma (Second Line)Phase 1/2NCT06904378
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)Phase 1NCT06639724Papers
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer